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Gregory L. Moneta, MD, Section EditorAspirin in Patients Undergoing Noncardiac Surgery
Devereaux PJ, Mrkobrada M, Sessler DI, et al; and the POISE-2
Investigators. N Engl J Med 2014;370:1494-503.
Conclusions: In patients undergoing noncardiac surgery administra-
tion of aspirin before surgery and throughout the early postsurgical period
has no effect on the rate of a composite of death or nonfatal myocardial
infarction but does increase risk of major bleeding.
Summary: Data from large randomized trials have shown the use of
aspirin can prevent myocardial infarction and major vascular events, with
high-dose aspirin not being superior to low-dose aspirin in preventing
vascular complications, and low-dose aspirin associated with a lower inci-
dence of gastric toxic effects. Among patients undergoing noncardiac sur-
gery there is a large amount of variability in the use of perioperative
aspirin, both among patients who are not already taking aspirin and among
those who are on long-term aspirin treatment. Because of the uncertain risks
and beneﬁts of aspirin in the perioperative period the authors conducted this
trial, POISE-2. The goal was to evaluate the effect of low-dose aspirin as
compared with placebo on the 30-day risk of a composite of death or
nonfatal myocardial infarction among patients undergoing noncardiac sur-
gery. The authors utilize a 2-by-2 factorial trial design, and randomly
assigned 10,010 patients preparing to undergo noncardiac surgery, who
were at risk for vascular complications to receive aspirin or placebo and
clonidine or placebo. This paper reports the results of the aspirin portion
of the trial. Patients were stratiﬁed according to whether or not they were
taking aspirin before the study (initiation stratum, 5628 patients) or they
were already on an aspirin (continuation stratum, 4382 patients). Patients
started taking aspirin (at a dose of 200 mg) or placebo just before surgery
and continued it daily (at a dose of 100 mg) for 30 days in the initiation stra-
tum and for 7 days in the continuation stratum, after which patients
resumed their regular aspirin regimen. The primary outcome was a compos-
ite of death or nonfatal myocardial infarction at 30 days. The primary
outcome occurred in 351 of 4998 patients (7.0%) in the aspirin group
and in 355 of 5012 patients (7.1%) in the placebo group (hazard ration
in the aspirin group 0.99; 95% CI, 0.86-1.15; P ¼ .92). Major bleeding
was more common in the aspirin group than in the placebo group (230 pa-
tients [4.6%] vs 188 patients [3.8%]; hazard ratio, 1.23; 95% CI, 1.01-1.49;
P ¼ .04). Primary and secondary outcome results were similar in the two
aspirin strata. There were also no differences when patients were stratiﬁed
with respect to nonvascular noncardiac surgery or vascular noncardiac sur-
gery or when they were stratiﬁed according to the revised Cardiac Risk In-
dex. There were also no differences in the aspirin and nonaspirin group in
patients with revised Cardiac Rick Index scores ranging from 0 to >4.
Comment: It has been dogma that patients undergoing vascular sur-
gery should be on aspirin to prevent cardiac complications in the periop-
erative period. The data suggests administration of aspirin prior to
noncardiac surgery, including noncardic vascular surgery and then
throughout the early postoperative period has no signiﬁcant effect on
rate of death or nonfatal myocardial infarction, but does increase risk of
bleeding. Therefore, if one chooses to withhold aspirin prior to noncardiac
surgery the question arises how long of time is it necessary to withhold
aspirin therapy. The authors point out that studies suggest hemostasis is
unimpaired if at least 20% of the platelets have normal Cox-1 activity.
This combined with the fact that 12% of circulating platelets are replaced
every 24 hours suggests stopping aspirin 72 or more hours before surgery
may be adequate to minimize risk of perioperative bleeding (Cerskus AL,
et al. Thromb Res 1980;18:389-97 and Bradlow BA, et al. Thromb Res
1982;27:99-110).
Lipidomics Proﬁling and Risk of Cardiovascular Disease in the
Prospective Population-Based Bruneck Study
Stegemann C, Pechlaner R, Willeit P, et al. Circulation 2014;129:1821-31.
Conclusions: Molecular lipid proﬁling is a promising new technique,
potentially better than conventional biochemical measures of lipid classes, to
identify population-based cohorts for increased risk of cardiovascular
disease.532Summary: The authors have identiﬁed previously that lipid proﬁling
of carotid endarterectomy specimens can distinguish between symptomatic
and asymptomatic plaques (Stegemann C et al, Circ Cardiovasc Genet
2011;4:232-42). Mass spectrometry (MS) is the preferred method for in-
depth studies of lipid-related pathomechanisms. MS can screen and simulta-
neously analyze molecular lipid species in nonseparated lipid extracts. In this
study, the authors performed lipidomics proﬁling in the prospective popula-
tion-based Bruneck Study and analyzed the association of 135 distinct lipid
species with cardiovascular disease risk over a 10-year observation period.
Goals were to identify new biomarkers for cardiovascular disease that are
perhaps superior to traditional ones for delineating risk of plaque destabili-
zation, rupture, and ultimately cardiovascular events. Lipids were extracted
from 685 plasma specimens from the Bruneck Study. Baseline evaluations
were performed in 2000. One hundred thirty-ﬁve lipid species from 8
different lipid classes were proﬁled by shotgun lipidomics with the use of
mass spectrometry. Levels of individual species of cholesterol esters (CEs),
lysophosphatidylcholines, phosphatidylcholines, phosphatidylethanolamines
(PEs), sphingomyelins, and triacylglycerols (TAGs) were associated with
cardiovascular disease over a 10-year observation period (2000-2010, 90
incident events). Among the lipid species with the strongest predictive value
were TAGs and CEs with a low carbon number and double-bond content,
including TAG (54:2) and CE (16:1), as well as PE (36:5) (P ¼ 5.1x107,
2.2x104, and 2.5x103, respectively). Consideration of these 3 lipid spe-
cies in addition to traditional risk factors resulted in improved risk discrim-
ination and classiﬁcation for cardiovascular disease (cross-validated DC
index, 0.0210; 95% CI, 0.0010-0.0422). There was also improvement in in-
tegrated discrimination (0.0212; 95% CI, 0.0031-0.0406), as well as
continuous net reclassiﬁcation index (0.398; 95% CI, 0.175-0.619).
Comment: It is well known the bulk of cardiovascular disease risk is
not well explained by traditional risk factors. The study suggests molecular
lipid proﬁling can result in signiﬁcant improvement in cardiovascular risk
discrimination beyond that of classic risk factors. This study is the ﬁrst to
use advanced mass spectrometry-based lipidomics proﬁling, potentially
identifying patients beneﬁting from primary prevention. An increased focus
on molecular lipid proﬁling rather than just classiﬁcation of lipids into classes
may provide improved stratiﬁcation of cardiovascular risk and better identi-
ﬁcation of patients in whom primary prevention is most indicated.
Racial and Regional Differences in Venous Thromboembolism in the
United States in Three Cohorts
Zakai NA, McClure LA, Judd SE, et al. Circulation 2014;129:1502-9.
Conclusions: There are racial and regional differences in venous
thromboembolism rates within the U.S.
Summary: Black Americans are thought to have higher rates of
venous thromboembolism (VTE) than white Americans. While potential
risk factors such as obesity, diabetes mellitus, and elevated factor VIII are
more common in blacks, there are genetic polymorphisms such as factor
V Leiden and the prothrombine gene 20210A mutation that are more com-
mon in whites (Zakai NA and McClure LA. J Thromb Haemost
2011;9:1877-82). The authors point out that previous studies on race
and VTE in the United States have been limited in that they examine
administrative databases, without validation of VTE events, had limited
numbers of black patients, and were from discrete geographic areas, or
excluded outpatient-treated DVTs. For this study, the authors assessed
VTE incidence in blacks and whites in three large cohorts: the Cardiovascu-
lar Health Study (CHS), the Atherosclerosis Risk in Communities Study
(ARIC), and the Reasons for Geographic and Racial Differences in Stroke
study (REGARDS). The studies together have followed up 51,149 individ-
uals over 439,090 person-years and have included 17,318 black Americans.
The association of race with VTE was tested with Cox proportional hazard
models adjusted for VTE risk factors. Over the 438,090 person-years, 916
incident VTE events (302 in blacks) occurred in the 51,149 individuals who
were followed up. With a risk factor-adjusted model, blacks had a higher
rate of VTE than whites in the CHS (hazard ratio, 1.81; 95% CI, 1.20-
2.73) but not ARIC (hazard ratio, 1.21; 95% CI, 0.96-1.54). In REGARDS
there was a signiﬁcant region-by-race interaction (P ¼ .01) with blacks in
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rest of the United States (hazard ratio, 1.63; 95% CI, 1.08-2.48). This
was not seen in whites (hazard ratio, 0.83; 95% CI, 0.61-1.14).
Comment: The study, as the authors point out, has several limitations
that include self-identiﬁcation of race, potential lack of generalizability of
the cohorts to the population of the U.S., as well as potential under ascer-
tainment of VTE events or biased assessment of VTE. Nevertheless, the data
may indicate previously unrecognized race-by-region interaction and varia-
tion in VTE incidents. Clearly, differences in VTE by race compared on a
regional, national or global scale will greatly inﬂuence associations of race
on VTE. Despite the study limitations it appears reasonable to advocate
for further studies of VTE in the United States in diverse geographic and
racial populations.
Randomized Clinical Trial of Selective Versus Routine Preoperative
Duplex Ultrasound Imaging Before Arteriovenous Fistula Surgery
Smith GE, Barnes R, Chetter IC BJS 2014;101:469-74.
Conclusions: When clinical evaluation detects anatomy suitable for
AV Fistula formation, perioperative duplex ultrasound vessel imaging may
not be needed.
Summary: Randomized clinical trials have supported the use of
duplex ultrasound over physical examination alone prior to construction
of arteriovenous ﬁstula (Ferring M et al, Clin J Am Soc Nephrol
2010;5:2236-44; and Wells AC et al, Br J Surg 2005;92:1439-43). Indeed,
routine duplex assessment of upper extremity arteries and veins prior to con-
struction of arteriovenous ﬁstula has become standard practice for many sur-
geons. However, the role of a selected duplex ultrasound imaging policy is
unknown and it may be possible that certain patients, if found to have suit-
able anatomy for construction of an arteriovenous ﬁstula by physical exam-
ination, do not require ultrasound conﬁrmation of these physical ﬁndings.
The author’s purpose was to compare a policy of selective vs routine ultra-
sound assessment before arteriovenous ﬁstula formation. All patients
referred for ﬁstula formation were assessed for inclusion in the study. Suit-
able patients were then randomized to either routine or selective preopera-
tive ultrasound imaging. Imaging was performed only when clinical criteria
were not met for construction of an arteriovenous ﬁstula. The primary
outcome measures were the site of AVF formation and 30-day primary fail-
ure rate, and secondary outcome measures included the rates of complica-
tions. There were 106 patients assessed and 94 were randomized into the
trial: 47 to selective and 47 to routine duplex ultrasonography. Groups
were well matched for age, co-morbidities and medications. The primary
failure rate was 29% overall. Primary failure was not statistically signiﬁcantly
different between the selective and routine imaging groups; 36% (14 of 39)
and 21% (8 of 38) respectively (P ¼ .144). The authors also noted no sig-
niﬁcant differences in the sites of AVF formation or complication rates.
Comment: This study is too small to advocate for adoption of only
selective use of duplex ultrasound prior to construction of arteriovenous ﬁs-
tula. The 15% increase in primary failure rates in the use of selective ultraso-
nography rather than routine ultrasonography while perhaps not statistically
signiﬁcant with the small numbers in the study, could potentially be clini-
cally signiﬁcant given the size of the arteriovenous ﬁstula population and
the potential for increased need for venous catheters with higher primary
failure rates of ﬁstula construction. Duplex ultrasound as a routine means
of assessment prior to placement of arteriovenous ﬁstula is both safe and
relatively inexpensive. There is no compelling evidence here to abandon
the use of routine ultrasound assessment of the upper extremity vessels prior
to placement of an arteriovenous ﬁstula.
Vertebral Artery Hypoplasia: Frequency and Effect on Cerebellar
Blood Flow Characteristics
Thierfelder KM, Baumann AB, Sommer WH, et al. Stroke 2014;45:1363-8.
Conclusions: Vertebral artery hypoplasia (VAH) is a frequent
anatomic variant and can lead to regional hypoperfusion in the posterior
inferior cerebellar artery (PICA).
Summary: The reported prevalence of VAH varies between 1.9% and
26.5%. This may, in fact, be due to lack of a standard deﬁnition of VAH.
Traditionally, VAH has generally been considered a harmless anatomic
variant. But in recent years there has been accumulating evidence that it
may constitute a risk factor for vertebrobasilar stroke, especially infarcts of
the PICA and lateral medullary area (Perren F et al, Neurology
2007;68:65-7). Currently computed tomography perfusion (CTP) is being
increasingly used to assess cerebral perfusion in the setting of acute stroke.
Whole-brain CT perfusion (WB-CTP) allows assessment of infratentorial
perfusion (Lee IH et al, Neuroradiology 2010;52:1095-100). The aim of
this study was to characterize the occurrence and hemodynamic effects of
VAH in the dependent PICA territory in the absence of posterior circulationischemia (PCI). The authors determined the frequency of VAH as assessed
by CT angiography (CTA) and characterized the effect of VAH perfusion of
the PICA territory using WB-CTP. Vertebral artery (VA) diameter was
retrospectively measured in 934 consecutive patients undergoing whole-
brain multimodal computed tomography because of suspected stroke.
VAH was deﬁned as a diameter of #2 mm and an asymmetry ratio of
#1:1.7 of the vertebral arteries. Blinded computed tomography perfusion
readings were performed in patients with VAH without PCI (MRI-
conﬁrmed) and in control patients (ratio 1:2) with normal VAs. There
were four different perfusion maps evaluated for relative hypoperfusion in
the PICA territory. VAH was found in 146 of 934 patients (15.6%). It
was found more frequently on the right side (66.1%). Of the 146 patients
with VAH, 59 without PCI qualiﬁed for computed tomography perfusion
analysis. Depending on the perfusion map, #42.4% (25/59) of patients
with VAH, but only 7.6% (9/118) without VAH showed ipsilateral PICA
hypoperfusion (P < .001). Sensitivities in patients with VAH were as fol-
lows: time to drain 42.4% (25/59) >mean transit time 39.0% (23/59),
>cerebral blood ﬂow 25.4% (15/59). Total cerebral blood volume was
not affected.
Comment: The study provides basic information about the relative
frequency and potential clinical importance of vertebral artery hypoplasia.
It suggests that vertebral artery hypoplasia confers an increased probability
of ischemic stroke in the PICA and lateral medullary distributions. Such im-
plications should be considered in patients with subclavian artery stenosis,
and patients in whom the left subclavian artery is to be covered by a thoracic
endograft.
Effect of Regional Cooperation on Outcomes From Ruptured
Abdominal Aortic Aneurysm
van Beek SC, Reimerink JJ, Vahl AC, et al; and the Amsterdam Acute
Aneurysm Trial Collaborators. Brit J Surg 2014;101:794-801.
Conclusions: Centralized care for ruptured AAA (rAAA) appears to
improve survival of patients with rAAA.
Summary: The overall mortality rate for ruptured abdominal aortic
aneurysm is estimated to be 80% with many of these patients not reaching
the hospital alive (Reimerink JJ et al, Br J Surg 2013;100:1405-13). There
is also evidence that higher caseloads of ruptured abdominal aortic aneurysm
(rAAA) decrease the surgical death rates and therefore advocates for central-
ization of care for RAA (Dimick JB et al, Ann Surg 2002;235:579-85; and
Visser P et al, Eur J Vasc Endovasc Surg 2005;30:359-64). From 2003, care
for patients with rAAA in the environs of Amsterdam of the Netherlands was
concentrated into three primary hospitals. These vascular centers provided
24-hour full emergency vascular services. Patients therefore with a suspected
rAAA were transported to a vascular center. Other hospitals in the area
referred patients to one of the vascular centers if the patient was judged
ﬁt for transport. The objective of this paper was to compare regional survival
after rAAA with institution of the centralized system with previous popula-
tion-based survival from the Netherlands. Additional objectives were to
determine the inﬂuence of hospital setting (intervention in a vascular center
or in a referring hospital) and of patient transfer (from a referring hospital to
a center, or not) on survival. Prior to implementation of centralized care for
rAAA in the Amsterdam area, previous population-based survival after rAAA
in the Netherlands was 46% (95% CI, 43%-49%). The hypothesis was that
regional cooperation would improve survival. The current study is a pro-
spective observation cohort study carried out simultaneously with the
Amsterdam Acute Aneurysm Trial. Consecutive patients with rAAA be-
tween 2004 and 2011 in all ten hospitals in the Amsterdam region were
included. Primary outcome was 30-day survival after admission. Multivari-
able logistic regression including comorbidities, sex, age, type of interven-
tion (endovascular vs open), preoperative systolic blood pressure,
cardiopulmonary resuscitation and year of intervention was used to assess
the inﬂuence of hospital setting on survival. Of 453 patients with rAAA
from the Amsterdam region, 61 did not undergo intervention, 352 patients
were treated surgically at a vascular center, and 40 at a referring hospital.
The regional survival rate was 58.5%, 265 0f 453, (95% CI, 53.9%-
62.9%). After multivariable adjustment, patients treated at a vascular center
had a higher survival rate than patients treated surgically at a referring hos-
pital (adjusted odds ratio, 3.18; 95% CI, 1.43-7.04).
Comment: There are a number of limitations to this study, especially
with generalization to results elsewhere. Obviously, Amsterdam is an urban
area and the conclusions may not be valid for more rural areas with longer
transport times. Nevertheless, in this study patient referral was not associ-
ated with impaired survival and it was possible to treat the majority of pa-
tients in a vascular center. We can conclude that at least in urban areas
there may be advantages in the care of patients with rAAAs to concentrate
the care of these patients in selected vascular centers rather than attempt to
treat them in every local hospital.
